Cargando…
CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications
BACKGROUND: Variation in the CYP2D6 gene may affect response to opioids in both poor and ultrarapid metabolizers, but data demonstrating such associations have been mixed, and the impact of variants on toxicity-related symptoms (e.g., nausea) is unclear. Therefore, we examined the association betwee...
Autores principales: | St Sauver, Jennifer L, Olson, Janet E, Roger, Veronique L, Nicholson, Wayne T, Black, John L, Takahashi, Paul Y, Caraballo, Pedro J, Bell, Elizabeth J, Jacobson, Debra J, Larson, Nicholas B, Bielinski, Suzette J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533497/ https://www.ncbi.nlm.nih.gov/pubmed/28769582 http://dx.doi.org/10.2147/PGPM.S136341 |
Ejemplares similares
-
Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics
por: Lopes, Guilherme S, et al.
Publicado: (2020) -
Participant perceived understanding and perspectives toward pharmacogenomics: Mayo Clinic Right Drug, Right Dose, Right Time (RIGHT) Protocol
por: Olson, Janet E., et al.
Publicado: (2017) -
Sex differences in type and occurrence of adverse reactions to opioid analgesics: a retrospective cohort study
por: Lopes, Guilherme S, et al.
Publicado: (2021) -
Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events
por: Zhu, Ye, et al.
Publicado: (2021) -
Are patients willing to incur out of pocket costs for pharmacogenomic testing?
por: Bielinski, Suzette J., et al.
Publicado: (2016)